Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment.
PET Clin
; 18(3): 409-418, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-36990945
ABSTRACT
Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP+ cancer-associated fibroblasts and, in some cancers, to FAP+ tumor cells; in addition, they indirectly irradiate FAP- cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Serina Endopeptidasas
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
PET Clin
Año:
2023
Tipo del documento:
Article